| TITLE |
DATE |
| Seattle Genetics to Present at Upcoming Investor Conference |
7-Dec-2011 |
| Seattle Genetics and Millennium Announce Presentation of ADCETRIS(TM)
Data at American Society of Hematology Annual Meeting |
8-Nov-2011 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
7-Nov-2011 |
| Seattle Genetics Reports Third Quarter 2011 Financial Results |
3-Nov-2011 |
| Seattle Genetics Appoints Vice President, Medical Affairs and
Announces Vice President, Quality Management Promotion |
26-Oct-2011 |
| Seattle Genetics Announces Initiation of a Phase II Clinical Trial of
ADCETRIS(TM) in CD30-Positive Non-Lymphoma Malignancies |
25-Oct-2011 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of
Third Quarter 2011 Financial Results on November 3, 2011 |
20-Oct-2011 |
| Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(TM)
(Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting |
24-Sep-2011 |
| Seattle Genetics and Oxford BioTherapeutics to Collaborate on
Antibody-Drug Conjugates for Cancer |
13-Sep-2011 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
8-Sep-2011 |
| Seattle Genetics Announces Initiation of a Phase II Clinical Trial of
ADCETRIS(TM) in CD30-Positive Non-Hodgkin Lymphoma |
23-Aug-2011 |
| Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS(TM)
(Brentuximab Vedotin) for Two Indications |
19-Aug-2011 |
| Seattle Genetics Reports Second Quarter 2011 Financial Results |
4-Aug-2011 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of
Second Quarter 2011 Financial Results on August 4, 2011 |
26-Jul-2011 |
| Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee in Favor of Accelerated Approval of ADCETRIS(TM) for Post-Transplant Relapsed Hodgkin Lymphoma and Relapsed or Refractory Systemic ALCL |
14-Jul-2011 |
| Trading of Seattle Genetics Common Stock Halted |
14-Jul-2011 |
| Seattle Genetics Achieves Milestone Under Millennium Collaboration
for European Medicines Agency Acceptance of Brentuximab Vedotin MAA |
27-Jun-2011 |
| Seattle Genetics Announces Promotion of Eric Dobmeier to Chief
Operating Officer |
17-Jun-2011 |
| Seattle Genetics Announces FDA Advisory Committee to Review
Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin
Lymphoma and Systemic ALCL |
16-Jun-2011 |
| Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab
Clinical Data at International Conference on Malignant Lymphoma |
15-Jun-2011 |
| Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting |
11-Jun-2011 |
| Millennium and Seattle Genetics Present Clinical Data on ADCETRIS(TM) (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting |
10-Jun-2011 |
| Seattle Genetics and Agensys, an Affiliate of Astellas, Announce
Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing
Collaboration |
9-Jun-2011 |
| Seattle Genetics and Millennium Present Updated Brentuximab Vedotin
(SGN-35) Data at ASCO Annual Meeting |
6-Jun-2011 |
| Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting |
6-Jun-2011 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
1-Jun-2011 |
| Millennium and Seattle Genetics Announce Brentuximab Vedotin (SGN-35)
Presentations at 16th Congress of the European
Hematology Association |
27-May-2011 |
| Seattle Genetics to Present Brentuximab Vedotin and SGN-75 Clinical
Data at the American Society of Clinical Oncology Annual Meeting |
19-May-2011 |
| Seattle Genetics Reports First Quarter 2011 Financial Results |
5-May-2011 |
| Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for
Filing and Grants Priority Review for Relapsed or Refractory Hodgkin
Lymphoma and Systemic ALCL |
2-May-2011 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
27-Apr-2011 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of
First Quarter 2011 Financial Results on May 5, 2011 |
26-Apr-2011 |
| Genmab and Seattle Genetics Expand Antibody-Drug Conjugate
Collaboration |
19-Apr-2011 |
| Seattle Genetics Appoints Vice President, Corporate Development and
Announces Management Promotion |
18-Apr-2011 |
| Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical
Development |
13-Apr-2011 |
| Seattle Genetics Reports Brentuximab Vedotin (SGN-35) Data at EBMT
Annual Meeting |
6-Apr-2011 |
| Seattle Genetics Highlights ADC Technology Research at AACR |
5-Apr-2011 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
30-Mar-2011 |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with
Abbott |
22-Mar-2011 |
| Seattle Genetics and Millennium Expand Antibody-Drug Conjugate
Collaboration |
15-Mar-2011 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
3-Mar-2011 |
| Seattle Genetics and Millennium Announce Initiation of a Phase I
Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy
for Front-line Systemic ALCL |
1-Mar-2011 |
| Seattle Genetics Submits BLA to FDA for Brentuximab Vedotin in
Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL |
28-Feb-2011 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
24-Feb-2011 |
| Seattle Genetics Reports Fourth Quarter and Year 2010 Financial
Results |
8-Feb-2011 |
| Seattle Genetics Announces Exercise of Over-Allotment Option |
3-Feb-2011 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of
Fourth Quarter and Year 2010 Financial Results on February 8, 2011 |
2-Feb-2011 |
| Seattle Genetics Prices Public Offering of Common Stock |
2-Feb-2011 |
| Seattle Genetics Announces Proposed Public Offering of Common Stock |
1-Feb-2011 |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with
Pfizer |
6-Jan-2011 |
| Seattle Genetics Announces Webcast of Presentation at J.P. Morgan
Healthcare Conference |
4-Jan-2011 |
| Seattle Genetics to Webcast Presentation at 2010 Deutsche Bank BioFEST |
13-Dec-2010 |
| Seattle Genetics and Millennium Report Positive Data from Phase II
Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at
ASH Annual Meeting |
7-Dec-2010 |
| Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting |
5-Dec-2010 |
| Seattle Genetics Announces Additions to Commercial Leadership Team |
30-Nov-2010 |
| Seattle Genetics to Present at Piper Jaffray Health Care Conference |
29-Nov-2010 |
| Seattle Genetics and Millennium to Present Brentuximab Vedotin
(SGN-35) Clinical Data at American Society of Hematology Annual Meeting |
8-Nov-2010 |
| Data from Brentuximab Vedotin (SGN-35) Phase I Clinical Trial
Published in New England Journal of Medicine |
3-Nov-2010 |
| Seattle Genetics Reports Third Quarter 2010 Financial Results |
1-Nov-2010 |
| Seattle Genetics to Present at Oppenheimer Healthcare Conference |
29-Oct-2010 |
| Seattle Genetics and Millennium to Highlight Brentuximab Vedotin
(SGN-35) at the International Symposium on Hodgkin Lymphoma |
25-Oct-2010 |
| Agensys, an Affiliate of Astellas, and Seattle Genetics Announce
Initiation of Phase I Clinical Trial of ASG-5ME for Prostate Cancer |
20-Oct-2010 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of
Third Quarter 2010 Financial Results on November 1, 2010 |
19-Oct-2010 |
| Seattle Genetics Reports Preliminary Data from Phase I Clinical Trial
of SGN-75 |
11-Oct-2010 |
| Seattle Genetics and Millennium Announce Positive Top-Line
Brentuximab Vedotin (SGN-35) Data from Phase II Trial in Relapsed or
Refractory ALCL |
11-Oct-2010 |
| Seattle Genetics to Present SGN-75 Clinical Data at the European
Society for Medical Oncology (ESMO) Congress |
4-Oct-2010 |
| Seattle Genetics and Millennium Announce Positive Top-Line
Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and
Refractory Hodgkin Lymphoma |
27-Sep-2010 |
| Seattle Genetics to Host Conference Call and Webcast on September 27,
2010 Regarding Top-line Data from Brentuximab Vedotin (SGN-35) Pivotal
Hodgkin Lymphoma Clinical Trial |
24-Sep-2010 |
| Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration |
14-Sep-2010 |
| Seattle Genetics Announces Phase IIb Trial of Lintuzumab (SGN-33) in
Patients with Acute Myeloid Leukemia (AML) Did Not Meet Primary Endpoint |
13-Sep-2010 |
| Seattle Genetics to Host Conference Call and Webcast on September 13,
2010 to Discuss Top-line Data from Lintuzumab (SGN-33) Phase IIb
Clinical Trial |
10-Sep-2010 |
| Seattle Genetics Announces Webcast Presentations at Upcoming Investor
Conferences |
7-Sep-2010 |
| Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate
Collaboration with Agensys, an Affiliate of Astellas |
2-Sep-2010 |
| Seattle Genetics to Present at the Canaccord Genuity 30th Annual Growth Conference |
4-Aug-2010 |
| Seattle Genetics Expands Antibody-Drug Conjugate Collaboration with Genentech |
3-Aug-2010 |
| Seattle Genetics Reports Second Quarter 2010 Financial Results and Continued Pipeline Progress |
27-Jul-2010 |
| Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Initiation of Phase I Clinical Trial of ASG-5ME for Pancreatic Cancer |
20-Jul-2010 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2010 Financial Results on July 27, 2010 |
19-Jul-2010 |
| Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma |
5-Jun-2010 |
| Seattle Genetics Announces Webcast Presentations at Upcoming Investor Conferences |
2-Jun-2010 |
| Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial |
24-May-2010 |
| Seattle Genetics Names Vice President, Sales and Announces Management Promotion |
24-May-2010 |
| Seattle Genetics and Millennium to Present Brentuximab Vedotin (SGN-35) Clinical Data at the American Society of Clinical Oncology Annual Meeting |
21-May-2010 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
28-Apr-2010 |
| Seattle Genetics Reports First Quarter 2010 Financial Results |
27-Apr-2010 |
| Seattle Genetics and Agensys, an Affiliate of Astellas, Report ASG-5ME Preclinical Data at AACR |
21-Apr-2010 |
| Seattle Genetics Highlights ADC and SEA Technologies at AACR |
21-Apr-2010 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2010 Financial Results on April 27, 2010 |
20-Apr-2010 |
| Seattle Genetics to Receive $9.5 Million Payment from Genentech to Extend Antibody-Drug Conjugate Collaboration |
20-Apr-2010 |
| Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma |
8-Apr-2010 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
12-Mar-2010 |
| Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio |
11-Mar-2010 |
| Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Collaboration with Genentech |
3-Mar-2010 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
25-Feb-2010 |
| Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial Outlook |
9-Feb-2010 |
| Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma |
3-Feb-2010 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2009 Financial Results on February 9, 2010 |
2-Feb-2010 |
| Seattle Genetics to Present at the J.P. Morgan Healthcare Conference |
5-Jan-2010 |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with GlaxoSmithKline |
21-Dec-2009 |
| Seattle Genetics and Millennium: The Takeda Oncology Company Announce
Strategic Collaboration for Novel Late-Stage Lymphoma Program
Brentuximab Vedotin (SGN-35) |
15-Dec-2009 |
| Seattle Genetics to Host Conference Call on December 15, 2009, to Discuss Brentuximab Vedotin (SGN-35) Partnering |
14-Dec-2009 |
| Seattle Genetics Announces Termination of Collaboration Agreement with Genentech for Dacetuzumab (SGN-40) |
11-Dec-2009 |
| Seattle Genetics to Present at 2009 Deutsche Bank Biotech Confab |
10-Dec-2009 |
| Seattle Genetics Reports Data from Dacetuzumab Phase Ib Combination
Clinical Trials |
7-Dec-2009 |
| Seattle Genetics Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in Lymphoma |
7-Dec-2009 |
| Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Data at the 51st American Society of Hematology Annual Meeting and Exposition |
1-Dec-2009 |
| Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration |
23-Nov-2009 |
| Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75 |
16-Nov-2009 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
27-Oct-2009 |
| Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results |
22-Oct-2009 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2009 Financial Results on October 22, 2009 |
15-Oct-2009 |
| Seattle Genetics Names Head of Commercial and Announces Management Promotion |
13-Oct-2009 |
| Seattle Genetics Announces Discontinuation of Dacetuzumab Phase IIb Diffuse Large B-Cell Lymphoma Clinical Trial |
5-Oct-2009 |
| Seattle Genetics to Present at JMP Securities Healthcare Focus Conference |
29-Sep-2009 |
| Seattle Genetics Introduces Novel Technology for Empowering Antibodies |
22-Sep-2009 |
| Seattle Genetics to Present at UBS Global Life Sciences Conference |
17-Sep-2009 |
| Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration With Bayer Schering Pharma |
8-Sep-2009 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
3-Sep-2009 |
| Seattle Genetics Completes Enrollment of Brentuximab Vedotin (SGN-35) Pivotal Trial for Patients with Hodgkin Lymphoma |
24-Aug-2009 |
| Seattle Genetics Announces Exercise of Over-Allotment Option |
13-Aug-2009 |
| Seattle Genetics Announces Pricing of Public Offering of Common Stock |
11-Aug-2009 |
| Seattle Genetics Announces Proposed Public Offering of Common Stock |
10-Aug-2009 |
| Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with MedImmune |
10-Aug-2009 |
| Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial |
24-Jul-2009 |
| Seattle Genetics Reports Strong Pipeline Progress and Second Quarter 2009 Financial Results |
23-Jul-2009 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2009 Financial Results on July 23, 2009 |
17-Jul-2009 |
| Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma |
18-Jun-2009 |
| Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma |
8-Jun-2009 |
| Seattle Genetics Presents Final Lintuzumab Phase I Clinical Data |
8-Jun-2009 |
| Seattle Genetics to Present at the Needham Life Sciences Conference |
4-Jun-2009 |
| Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma |
1-Jun-2009 |
| Seattle Genetics to Present SGN-35 and Lintuzumab Clinical Data at the European Hematology Association Congress |
21-May-2009 |
| Seattle Genetics Announces SGN-35 Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting |
14-May-2009 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
8-May-2009 |
| Seattle Genetics Reports Product Development Progress and First Quarter 2009 Financial Results |
23-Apr-2009 |
| Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR |
22-Apr-2009 |
| Seattle Genetics Highlights Dacetuzumab Preclinical Research at AACR |
21-Apr-2009 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2009 Financial Results on April 23, 2009 |
16-Apr-2009 |
| Seattle Genetics Announces Management Team Addition and Promotion to Support SGN-35 Commercialization Initiatives |
7-Apr-2009 |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration With Millennium |
6-Apr-2009 |
| Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma |
30-Mar-2009 |
| Seattle Genetics to Present at the Needham Cancer Therapeutics Conference |
24-Mar-2009 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
4-Mar-2009 |
| Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia |
25-Feb-2009 |
| Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin Lymphoma |
19-Feb-2009 |
| Seattle Genetics Reports Fourth Quarter and Year 2008 Financial Results and Provides 2009 Financial Outlook |
5-Feb-2009 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2008 Financial Results on February 5, 2009 |
29-Jan-2009 |
| Seattle Genetics Announces Pricing of Common Stock Offering |
28-Jan-2009 |
| Seattle Genetics Receives Orphan Drug Designations for SGN-35 in the United States and Europe |
26-Jan-2009 |
| Seattle Genetics Receives Special Protocol Assessment for SGN-35 Pivotal Trial in Hodgkin Lymphoma |
21-Jan-2009 |
| Seattle Genetics to Present at the J.P. Morgan Healthcare Conference |
6-Jan-2009 |
| Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial |
10-Dec-2008 |
| Seattle Genetics Reports Durable Objective Responses with SGN-35 in Lymphoma |
6-Dec-2008 |
| Seattle Genetics Reports Objective Responses with Dacetuzumab in Phase II Non-Hodgkin Lymphoma Trial |
6-Dec-2008 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
1-Dec-2008 |
| Seattle Genetics to Present at the Oppenheimer Healthcare Conference |
29-Oct-2008 |
| Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting |
28-Oct-2008 |
| Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs |
24-Oct-2008 |
| Seattle Genetics Reports Development Progress and Third Quarter 2008 Financial Results |
23-Oct-2008 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2008 Financial Results on October 23, 2008 |
16-Oct-2008 |
| Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with Progenics |
15-Oct-2008 |
| Seattle Genetics Adds to Senior Management Team |
30-Sep-2008 |
| Seattle Genetics to Present at the UBS Global Life Sciences Conference |
17-Sep-2008 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
27-Aug-2008 |
| Seattle Genetics Initiates SGN-70 Phase I Clinical Trial |
31-Jul-2008 |
| Seattle Genetics Reports Second Quarter 2008 Financial Results |
22-Jul-2008 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2008 Financial Results on July 22, 2008 |
15-Jul-2008 |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi Sankyo |
8-Jul-2008 |
| Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration Triggered by Genentech's IND Filing |
18-Jun-2008 |
| Seattle Genetics Announces SGN-35 Plenary Presentation at International Conference on Malignant Lymphoma |
6-Jun-2008 |
| Seattle Genetics Reports Final SGN-40 Phase I Non-Hodgkin Lymphoma Data at International Conference on Malignant Lymphoma |
5-Jun-2008 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
4-Jun-2008 |
| Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma |
3-Jun-2008 |
| Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma |
2-Jun-2008 |
| Seattle Genetics Announces Upcoming SGN-35 Presentation at the American Society of Clinical Oncology Annual Meeting |
16-May-2008 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
6-May-2008 |
| Seattle Genetics Reports First Quarter 2008 Financial Results |
24-Apr-2008 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2008 Financial Results on April 24, 2008 |
17-Apr-2008 |
| Seattle Genetics Presents Preclinical Data on its Antibody-Drug Conjugate Technology and SGN-33 Program at AACR |
15-Apr-2008 |
| Seattle Genetics Highlights SGN-70 at AAI Annual Meeting |
9-Apr-2008 |
| Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma |
8-Apr-2008 |
| Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial |
28-Mar-2008 |
| Seattle Genetics Initiates SGN-33 Clinical Trial in Combination with Revlimid(R) for Myelodysplastic Syndromes (MDS) |
20-Mar-2008 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
12-Mar-2008 |
| Seattle Genetics to Present at BIO CEO & Investor Conference |
8-Feb-2008 |
| Seattle Genetics Reports Fourth Quarter 2007 Financial Results and Provides 2008 Financial Outlook |
7-Feb-2008 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year End 2007 Financial Results on February 7, 2008 |
31-Jan-2008 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
25-Jan-2008 |
| Seattle Genetics Announces Completion of Common Stock Offering, Including Exercise of Over-Allotment Option |
24-Jan-2008 |
| Seattle Genetics Announces Pricing of Public Offering of Common Stock |
18-Jan-2008 |
| Seattle Genetics Announces Proposed Public Offering of Common Stock |
14-Jan-2008 |
| Seattle Genetics Earns Milestone Payment from Initiation of SGN-40 Phase Ib Clinical Trial in Combination with Rituxan for Non-Hodgkin Lymphoma |
7-Jan-2008 |
| Seattle Genetics to Present at the 26th Annual JPMorgan Healthcare Conference |
4-Jan-2008 |
| Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASH |
10-Dec-2007 |
| Seattle Genetics to Participate on Panel at RBC Capital Markets Healthcare Conference |
7-Dec-2007 |
| Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination with Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma |
7-Dec-2007 |
| Seattle Genetics to Host Research and Development Day on December 12, 2007 |
5-Dec-2007 |
| Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia |
9-Nov-2007 |
| Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma |
5-Nov-2007 |
| Seattle Genetics Initiates SGN-40 Clinical Trial in Combination with Revlimid for Multiple Myeloma |
1-Nov-2007 |
| Seattle Genetics and MedImmune Expand Antibody-Drug Conjugate Collaboration |
31-Oct-2007 |
| Seattle Genetics to Present at the CIBC World Markets Annual Healthcare Conference |
30-Oct-2007 |
| Seattle Genetics Reports Preclinical Data on SGN-40 and an Anti-CD19 Antibody-Drug Conjugate |
24-Oct-2007 |
| Seattle Genetics Reports Third Quarter 2007 Financial Results and Progress in Advancing Pipeline |
23-Oct-2007 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2007 Results on October 23, 2007 |
16-Oct-2007 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
6-Sep-2007 |
| Seattle Genetics Reports Second Quarter 2007 Financial Results and Highlights Pipeline Progress |
25-Jul-2007 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2007 Results on July 25, 2007 |
17-Jul-2007 |
| Seattle Genetics Adds Industry Veterans John P. McLaughlin and Daniel G. Welch to its Board of Directors and Promotes Eric Dobmeier to Chief Business Officer |
14-Jun-2007 |
| Seattle Genetics to Present at Upcoming Investor Conferences |
25-May-2007 |
| Seattle Genetics Reports First Quarter 2007 Financial Results and Corporate Accomplishments |
24-Apr-2007 |
| Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR |
17-Apr-2007 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2007 Results on April 24, 2007 |
17-Apr-2007 |
| Seattle Genetics Announces Multiple Presentations at Upcoming American Association for Cancer Research Annual Meeting |
10-Apr-2007 |
| Seattle Genetics to Present at the CIBC World Markets Biotechnology and Specialty Pharmaceuticals Conference |
9-Apr-2007 |
| Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech |
27-Mar-2007 |
| Seattle Genetics Appoints Dr. Tom Reynolds Chief Medical Officer |
20-Mar-2007 |
| Seattle Genetics to Present at the Susquehanna Financial Group Healthcare Conference |
26-Feb-2007 |
| Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs |
13-Feb-2007 |
| Seattle Genetics to Present at the BIO CEO & Investor Conference |
9-Feb-2007 |
| Seattle Genetics Reports Fourth Quarter and Year-End 2006 Results and Provides 2007 Financial Outlook |
6-Feb-2007 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year End 2006 Results on February 6, 2007 |
30-Jan-2007 |
| Seattle Genetics to Present at the JPMorgan Annual Healthcare Conference |
8-Jan-2007 |
| Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for Development and Commercialization of SGN-40 |
8-Jan-2007 |
| Seattle Genetics and Agensys Announce Collaboration to Co-Develop and Commercialize Antibody-Drug Conjugate Therapies for Cancer |
8-Jan-2007 |
| Seattle Genetics Initiates Phase II Clinical Trial of SGN-40 for the Treatment of Non-Hodgkin's Lymphoma |
20-Dec-2006 |
| Seattle Genetics Announces Advancements in Development Programs at American Society of Hematology Meeting |
12-Dec-2006 |
| Seattle Genetics to Participate on Panel at RBC Capital Markets Healthcare Conference |
8-Dec-2006 |
| Seattle Genetics Announces Upcoming Presentations at the American Society of Hematology Annual Meeting |
1-Dec-2006 |
| Seattle Genetics Initiates Phase I Clinical Trial of SGN-35 |
17-Nov-2006 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
2-Nov-2006 |
| Seattle Genetics Reports Third Quarter 2006 Financial Results and Pipeline Progress |
24-Oct-2006 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2006 Results on October 24, 2006 |
17-Oct-2006 |
| Seattle Genetics to Present at the BIO Investor Forum |
12-Oct-2006 |
| Seattle Genetics to Present at the UBS Global Life Sciences Conference |
21-Sep-2006 |
| Seattle Genetics Reports Second Quarter 2006 Financial Results and Pipeline Progress |
25-Jul-2006 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2006 Results on July 25, 2006 |
18-Jul-2006 |
| Seattle Genetics to Present at the C.E. Unterberg, Towbin Emerging Growth Conference |
6-Jul-2006 |
| Seattle Genetics Achieves Milestone Under Antibody-Drug Conjugate Collaboration with CuraGen |
22-Jun-2006 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
9-Jun-2006 |
| Seattle Genetics Reports Encouraging SGN-40 Clinical Data at the American Society of Clinical Oncology Annual Meeting |
5-Jun-2006 |
| Seattle Genetics Announces Closing of Common Stock Sale |
25-May-2006 |
| Seattle Genetics Names Pamela Trail, Ph.D., as Chief Scientific Officer |
16-May-2006 |
| Seattle Genetics to Present at the Bank of America Health Care Conference |
15-May-2006 |
| Seattle Genetics Reports on SGN-30 Cutaneous ALCL Phase II Clinical Trial at the Society of Investigative Dermatology Meeting |
4-May-2006 |
| Seattle Genetics Reports First Quarter 2006 Financial Results |
25-Apr-2006 |
| Seattle Genetics and Laureate Pharma Announce Manufacturing Agreement |
25-Apr-2006 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2006 Results on April 25, 2006 |
18-Apr-2006 |
| Seattle Genetics Receives Key Anti-CD30 Patent Claims |
11-Apr-2006 |
| Seattle Genetics to Present at the BIO 2006 Convention |
10-Apr-2006 |
| Seattle Genetics Reports Continued Advances with SGN-70 and Its ADC Technology at the AACR Annual Meeting |
4-Apr-2006 |
| Seattle Genetics Announces Closing of Common Stock Offering |
3-Apr-2006 |
| Seattle Genetics Announces Proceeds of Common Stock Offering |
30-Mar-2006 |
| Seattle Genetics Announces Common Stock Offering |
28-Mar-2006 |
| Seattle Genetics to Present at Invest Northwest Conference |
17-Mar-2006 |
| Seattle Genetics Appoints Dr. Daniel Hoth to Board of Directors |
10-Mar-2006 |
| Seattle Genetics to Present at the BIO CEO and Investor Conference |
8-Feb-2006 |
| Seattle Genetics Reports Fourth Quarter and Year 2005 Financial Results |
7-Feb-2006 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2005 Results on February 7, 2006 |
31-Jan-2006 |
| Seattle Genetics to Present at the 24th Annual JPMorgan Healthcare Conference |
5-Jan-2006 |
| Seattle Genetics Reports Preclinical Data on its SGN-40 and SGN-70 Programs at the American Society of Hematology Annual Meeting |
13-Dec-2005 |
| Seattle Genetics Reports on SGN-30 Clinical Program at the American Society of Hematology Annual Meeting |
12-Dec-2005 |
| Seattle Genetics Reports SGN-40 Clinical Data at the American Society of Hematology Annual Meeting |
12-Dec-2005 |
| Seattle Genetics Expands SGN-40 Clinical Program into Chronic Lymphocytic Leukemia |
29-Nov-2005 |
| Seattle Genetics Initiates SGN-33 Clinical Trial |
17-Nov-2005 |
| Seattle Genetics to Present on ADC Technology at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
14-Nov-2005 |
| Seattle Genetics to Present at CIBC World Markets Annual Healthcare Conference |
3-Nov-2005 |
| Seattle Genetics Reports Third Quarter 2005 Financial Results |
25-Oct-2005 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2005 Financial Results |
18-Oct-2005 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
13-Oct-2005 |
| Seattle Genetics Expands Patent Portfolio for SGN-40 Program |
4-Oct-2005 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
19-Sep-2005 |
| Seattle Genetics Appoints Todd Simpson as New Chief Financial Officer |
23-Aug-2005 |
| Celera Genomics and Seattle Genetics Announce Target Selection from Research Collaboration in Cancer |
18-Aug-2005 |
| Seattle Genetics Adds Richard Flavell, Ph.D., to Scientific Advisory Board |
4-Aug-2005 |
| Seattle Genetics Reports Second Quarter 2005 Financial Results |
26-Jul-2005 |
| Seattle Genetics Provides Update on SGN-15 Phase II Clinical Program at the World Conference on Lung Cancer |
6-Jul-2005 |
| Seattle Genetics and PSMA Development Company Announce Antibody-Drug Conjugate Collaboration |
20-Jun-2005 |
| Seattle Genetics Presents Data from SGN-35 Program at International Conference on Malignant Lymphoma |
10-Jun-2005 |
| Seattle Genetics to Present at Pacific Growth Equities Life Sciences Growth Conference |
6-Jun-2005 |
| Seattle Genetics to Present at the Needham Biotechnology Conference |
23-May-2005 |
| Seattle Genetics Provides Update on SGN-30 and SGN-40 Clinical Programs at ASCO |
16-May-2005 |
| Seattle Genetics to Present at the Banc of America Securities Health Care Conference |
12-May-2005 |
| Seattle Genetics Launches Manufacturing Campaign with Albany Molecular Research |
5-May-2005 |
| Seattle Genetics Receives U.S. Patent Relating to Its Antibody-Drug Conjugate Technology |
3-May-2005 |
| Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with MedImmune |
28-Apr-2005 |
| Seattle Genetics Reports First Quarter 2005 Results |
26-Apr-2005 |
| Seattle Genetics to Present at Invest Northwest Conference |
21-Apr-2005 |
| Seattle Genetics to Present Advances in Preclinical Pipeline and ADC Technology at AACR Annual Meeting |
14-Apr-2005 |
| Seattle Genetics In-licenses Anti-CD33 Antibody Program from Protein Design Labs |
13-Apr-2005 |
| Seattle Genetics to Present at CIBC Biotechnology & Specialty Pharmaceuticals Conference |
31-Mar-2005 |
| Seattle Genetics Announces Changes to Board of Directors; Appoints Industry Veteran David Gryska |
29-Mar-2005 |
| Seattle Genetics Achieves Milestone under Antibody-Drug Conjugate Agreement with Genentech |
15-Mar-2005 |
| Seattle Genetics Promotes Eric Dobmeier to Senior Vice President, Corporate Development |
28-Feb-2005 |
| Seattle Genetics to Present at Two Upcoming Investor Conferences |
18-Feb-2005 |
| Seattle Genetics and CuraGen Expand Antibody-Drug Conjugate Collaboration |
15-Feb-2005 |
| Seattle Genetics Reports Fourth Quarter and Year 2004 Results |
8-Feb-2005 |
| Seattle Genetics to Host Conference Call and Webcast Discussion of 2004 Financial Results |
27-Jan-2005 |
| Seattle Genetics Receives Key U.S. Patents for SGN-40 Program |
19-Jan-2005 |
| Seattle Genetics to Present at JPMorgan Healthcare Conference |
6-Jan-2005 |
| Seattle Genetics Reports on SGN-30 and SGN-40 Clinical Programs at the American Society of Hematology Annual Meeting |
6-Dec-2004 |
| Seattle Genetics Expands SGN-40 Clinical Program into Non-Hodgkin's Lymphoma |
2-Dec-2004 |
| Seattle Genetics to Present at Lazard Life Sciences Conference |
29-Nov-2004 |
| Seattle Genetics Files Shelf Registration Statement |
23-Nov-2004 |
| Seattle Genetics and Genentech Expand Antibody-Drug Conjugate Collaboration |
9-Nov-2004 |
| Seattle Genetics to Participate in Upcoming Investor Conferences |
8-Nov-2004 |
| Seattle Genetics Reports Third Quarter 2004 Financial Results |
26-Oct-2004 |
| Seattle Genetics Announces Senior Research & Development Appointments |
19-Oct-2004 |
| Seattle Genetics to Present at BIO Emerging Company Investor Forum |
6-Oct-2004 |
| Seattle Genetics Announces Antibody-Drug Conjugate Agreement with Bayer Pharmaceuticals |
28-Sep-2004 |
| Seattle Genetics Initiates SGN-30 Phase II Clinical Trial for Cutaneous Lymphoma |
23-Sep-2004 |
| Seattle Genetics to Participate in Two Upcoming Investor Conferences |
15-Sep-2004 |
| Seattle Genetics Announces Douglas Williams to Step Down as Chief Scientist; Will Remain on Board of Directors |
7-Sep-2004 |
| Seattle Genetics to Present at NewsMakers in the Biotech Industry Conference |
2-Sep-2004 |
| Seattle Genetics Receives Orphan Drug Designation for SGN-40 in Multiple Myeloma |
24-Aug-2004 |
| Seattle Genetics Reports Second Quarter 2004 Financial Results |
27-Jul-2004 |
| Seattle Genetics Initiates SGN-15 Phase II Biomarker Clinical Trial |
23-Jul-2004 |
| Celera Genomics & Seattle Genetics Announce Collaboration to Co-Develop Targeted Antibody Therapies for Cancer |
21-Jul-2004 |
| Seattle Genetics Establishes Preferred Antibody-Drug Conjugate Manufacturing Relationship with Albany Molecular Research, Inc. |
13-Jul-2004 |
| Seattle Genetics Appoints Biotechnology Expert Franklin Berger to Board of Directors |
1-Jul-2004 |
| Seattle Genetics and CuraGen Announce Antibody-Drug Conjugate (ADC) Agreement |
22-Jun-2004 |
| Seattle Genetics Reports on SGN-15 Clinical Program at ASCO |
5-Jun-2004 |
| Seattle Genetics to Present at Three Conferences in June |
3-Jun-2004 |
| Seattle Genetics Expands Research Programs Through Exclusive License from Imperial College London |
19-May-2004 |
| Seattle Genetics to Present at Two Upcoming Conferences |
18-May-2004 |
| Seattle Genetics Added to NASDAQ Biotechnology Index |
17-May-2004 |
| Seattle Genetics Reports First Quarter 2004 Results |
27-Apr-2004 |
| Seattle Genetics to Present at CIBC World Markets Conference |
22-Apr-2004 |
| Seattle Genetics Names Clay B. Siegall, Ph.D., Interim Chairman of the Board |
1-Apr-2004 |
| Seattle Genetics Initiates SGN-40 Phase I Clinical Trial in Multiple Myeloma |
25-Mar-2004 |
| Seattle Genetics to Present Advances in Preclinical Research at AACR Annual Meeting |
24-Mar-2004 |
| Seattle Genetics Receives Orphan Drug Designation for SGN-30 in T-Cell Lymphomas |
26-Feb-2004 |
| Seattle Genetics Announces Manufacturing Agreement with Abbott Laboratories |
24-Feb-2004 |
| Seattle Genetics to Host Conference Call on February 26, 2004 |
19-Feb-2004 |
| Seattle Genetics to Present at BIO CEO & Investor Conference |
18-Feb-2004 |
| Seattle Genetics Announces Completion of $66 Million Stock Offering |
10-Feb-2004 |
| Seattle Genetics Announces Pricing of Common Stock Offering |
5-Feb-2004 |
| Seattle Genetics Reports Fourth Quarter and Year 2003 Results |
3-Feb-2004 |
| Seattle Genetics Announces Proposed Common Stock Offering |
26-Jan-2004 |
| Seattle Genetics Advances SGN-30 to Phase II Clinical Study |
22-Jan-2004 |
| Seattle Genetics Announces Expansion of ADC Collaboration with Protein Design Labs |
12-Jan-2004 |
| Seattle Genetics to Present at JPMorgan Healthcare Conference |
7-Jan-2004 |
| Seattle Genetics Announces That Protein Design Labs Has Taken An Exclusive Antigen License Under ADC Collaboration |
23-Dec-2003 |
| Seattle Genetics Receives Additional $10 Million From Genentech Under Antibody-Drug Conjugate Collaboration |
19-Dec-2003 |
| Seattle Genetics Announces Filing of Shelf Registration Statement |
17-Dec-2003 |
| Seattle Genetics Reports Data on its SGN-30 and SGN-40 Programs at the American Society of Hematology Annual Meeting |
8-Dec-2003 |
| Seattle Genetics Announces H. Perry Fell, Ph.D., To Become Consultant to the Company |
5-Dec-2003 |
| Seattle Genetics Adds Two Oncology Veterans to Scientific Advisory Board |
11-Nov-2003 |
| Seattle Genetics to Present at CIBC World Markets Healthcare Conference |
5-Nov-2003 |
| Seattle Genetics Names Dr. Michael McDonald Chief Medical Officer |
4-Nov-2003 |
| Seattle Genetics Reports Third Quarter 2003 Results |
28-Oct-2003 |
| Seattle Genetics to Present at Rodman & Renshaw Techvest Healthcare Conference |
15-Oct-2003 |
| Seattle Genetics to Present at ThinkEquity Partners Growth Conference |
9-Sep-2003 |
| Seattle Genetics Promotes Eric Dobmeier to Vice President, Corporate Affairs |
3-Sep-2003 |
| Seattle Genetics Reports Encouraging SGN-15 Data at World Conference on Lung Cancer |
12-Aug-2003 |
| Seattle Genetics Reports Progress in its SGN-35 Program |
11-Aug-2003 |
| Seattle Genetics Reports Second Quarter 2003 Results |
29-Jul-2003 |
| Seattle Genetics and Genencor International Extend Collaboration Agreement |
29-Jul-2003 |
| Seattle Genetics Receives Orphan Drug Designation from the FDA for SGN-30 |
28-Jul-2003 |
| Seattle Genetics Names Douglas Williams, Ph.D., Chief Scientific Officer and Executive Vice President, R&D |
17-Jul-2003 |
| Seattle Genetics' Stockholders Approve $41 Million Financing |
2-Jul-2003 |
| Seattle Genetics Achieves Milestones Under Antibody-Drug Conjugate Collaboration with Celltech Group |
17-Jun-2003 |
| Seattle Genetics Publishes Preclinical Antibody-Drug Conjugate Technology Research In Nature Biotechnology |
5-Jun-2003 |
| Seattle Genetics Reports Progress In Clinical Development of Antibody-Based Therapies for Cancer; Company presents data from four clinical studies at ASCO 2003 Annual Meeting |
2-Jun-2003 |
| Seattle Genetics Announces Definitive Agreement for $40 Million Financing |
13-May-2003 |
| Seattle Genetics Scheduled to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference |
28-Apr-2003 |
| Seattle Genetics Reports First Quarter 2003 Results |
22-Apr-2003 |
| Seattle Genetics Reports Antibody-Drug Conjugate Research Data |
8-Apr-2003 |
| Seattle Genetics Scheduled to Present at Invest Northwest 2003 |
6-Mar-2003 |
| Seattle Genetics Announces Key Scientific Additions |
19-Feb-2003 |
| Seattle Genetics Reports Fourth Quarter and Year 2002 Results |
30-Jan-2003 |
| Seattle Genetics Scheduled to Present at JPMorgan H&Q Healthcare Conference |
2-Jan-2003 |
| Clinical Data on Seattle Genetics Monoclonal Antibody SGN-30 To Be Presented at American Society of Hematology Annual Meeting |
5-Dec-2002 |
| Seattle Genetics Announces Appointment of Clay B. Siegall, Ph.D. as Chief Executive Officer |
27-Nov-2002 |
| Seattle Genetics Advances SGN-30 to Multi-Dose Phase I/II Clinical Trial, Provides Update On SGN-15 and Closes Its SGN-10 Clinical Program |
7-Nov-2002 |
| Seattle Genetics Scheduled to Present at CIBC World Markets Thirteenth Annual Health Care Conference |
31-Oct-2002 |
| Seattle Genetics Reports Third Quarter 2002 Results |
22-Oct-2002 |
| Seattle Genetics Provides Update On SGN-14 |
8-Oct-2002 |
| Seattle Genetics Enters Into Manufacturing Relationship With Albany Molecular Research |
7-Oct-2002 |
| Seattle Genetics Awarded National Institutes of Health Funded Research Grant |
17-Sep-2002 |
| Seattle Genetics Names Peter D. Senter Vice President, Chemistry |
6-Sep-2002 |
| Seattle Genetics Reports Findings From SGN-30 Phase I Clinical Study |
4-Sep-2002 |
| Seattle Genetics Initiates Phase II Clinical Trial of SGN-15 in Advanced Ovarian Cancer |
20-Aug-2002 |
| Seattle Genetics Reports Second Quarter 2002 Results |
23-Jul-2002 |
| Seattle Genetics Receives License Fee From Genencor |
22-Jul-2002 |
| Seattle Genetics Publishes Preclinical Findings of Monoclonal Antibody SGN-30 In Cancer Research |
11-Jul-2002 |
| Seattle Genetics Appoints Douglas Southern to Board of Directors |
4-Jun-2002 |
| Seattle Genetics Updates Clinical Progress and Plans |
21-May-2002 |
| Seattle Genetics Scheduled to Present at CIBC World Markets Biotechnology & Specialty Pharmaceuticals Conference |
29-Apr-2002 |
| Seattle Genetics Releases First Quarter 2002 Results |
25-Apr-2002 |
| Seattle Genetics Announces Antibody-Drug Conjugate Agreement With Genentech |
22-Apr-2002 |
| Seattle Genetics to Present Preclinical Data at AACR Meeting |
8-Apr-2002 |
| Seattle Genetics Names CEO as Chairman and Appoints General Counsel |
1-Apr-2002 |
| Celltech and Seattle Genetics Announce Antibody-Drug Conjugate Collaboration |
28-Mar-2002 |
| Seattle Genetics Initiates Phase I Clinical Trial with Monoclonal Antibody SGN-30 |
21-Mar-2002 |
| Seattle Genetics Licenses Monoclonal Antibodies from Mabtech AB |
14-Mar-2002 |
| Seattle Genetics Reports Fourth Quarter and Year 2001 Results |
31-Jan-2002 |
| Seattle Genetics Announces That Its Anti-CD40 Monoclonal Antibody Enters Clinical Development At Genentech |
8-Jan-2002 |
| Genencor and Seattle Genetics Announce Collaboration To Advance Targeted Cancer Therapies |
7-Jan-2002 |
| Seattle Genetics Appoints New Member to its Scientific Advisory Board |
4-Jan-2002 |
| Seattle Genetics Scheduled to Present at JPMorgan H&Q Healthcare Conference |
3-Jan-2002 |
| Seattle Genetics Scheduled to Present at CIBC Healthcare Conference |
1-Nov-2001 |
| Seattle Genetics Reports Third Quarter 2001 Results |
23-Oct-2001 |
| Seattle Genetics Licenses Potent Cell-Killing Drugs from Proacta Therapeutics |
22-Oct-2001 |
| Seattle Genetics Scheduled to Present at UBS Warburg Global Life Sciences Conference |
5-Oct-2001 |
| Seattle Genetics Scheduled at Raymond James Healthcare Conference |
26-Sep-2001 |
| Seattle Genetics Awarded National Institutes of Health Funded Research Grant |
19-Sep-2001 |
| Seattle Genetics Initiates Phase II Clinical Trial with SGN-15 in Lung Cancer |
21-Aug-2001 |
| Seattle Genetics Announces Business Update Meeting and Webcast |
16-Aug-2001 |
| Seattle Genetics Signs Development and Manufacturing Agreement with ICOS for the Monoclonal Antibody Component of SGN-15 |
14-Aug-2001 |
| Seattle Genetics Announces Relocation and Expansion of Corporate Headquarters |
14-Aug-2001 |
| Seattle Genetics Reports Second Quarter 2001 Results |
24-Jul-2001 |
| Seattle Genetics Licenses Monoclonal Antibodies from CLB-Research and Development |
18-Jul-2001 |
| Seattle Genetics Announces Date of Second Quarter Results and Conference Call |
11-Jul-2001 |
| Seattle Genetics Names Morris Rosenberg Vice President, Development |
10-Jul-2001 |
| Seattle Genetics Added to Russell 2000 and Russell 3000 Stock Indexes |
10-Jul-2001 |
| Seattle Genetics and Eos Biotechnology Collaborate To Develop Next Generation Antibody-Drug Conjugates For Cancer Therapy |
5-Jun-2001 |
| Seattle Genetics Appoints New Members to its Board of Directors and Scientific Advisory Board |
17-May-2001 |
| Seattle Genetics Scheduled at CIBC World Markets Bio-Technology Conference |
1-May-2001 |
| Seattle Genetics Reports First Quarter Results |
24-Apr-2001 |
| Seattle Genetics Announces Initial Public Offering |
7-Mar-2001 |
| Seattle Genetics and Medarex Establish Alliance to Develop Human Antibody Therapeutics |
7-Feb-2001 |
| Seattle Genetics Initiates Phase II Clinical Trial in Prostate Cancer |
30-Nov-2000 |
| Seattle Genetics Files For Initial Public Offering of Common Stock |
20-Nov-2000 |
| Seattle Genetics Signs Development and Manufacturing Agreement with ICOS |
9-Nov-2000 |
| Seattle Genetics Initiates Phase II Clinical Trials With SGN-15 |
31-Oct-2000 |
 |
